FDA Clearance Tracker · K240773
VisAble.IO
Last checked: Nov 19, 2026Latest source record: Apr 15, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Apr 15, 2024
Substantially Equivalent
Time to decision
25 days
Received Mar 21, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K240773
- Device name
- VisAble.IO
- Applicant
- Techsomed
- Applicant location
- Rehovot, IL
- Received
- Mar 21, 2024
- Decided
- Apr 15, 2024
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Radiological Image Processing Software For Ablation Therapy Planning And Evaluation (QTZ)
- Device class
- Class II
- Regulation
- 21 CFR 892.2050
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QTZ. The earliest in FDA's data is K220256, decided Oct 7, 2022.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K240773
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Techsomed
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- BioTraceIO Vision (V1.7)510(k)
K251931 · Decided Sep 8, 2025 · 76 days after receipt
Device type: Radiological Image Processing Software For Ablation Therapy Planning And Evaluation (QTZ) · Radiology & Imaging
K243084 · Decided Dec 27, 2024 · 88 days after receipt
Device type: Post-Ablation Tissue Response Prediction Software (QZL) · Radiology & Imaging
- BioTraceIO LiteNew device typeDe Novo
DEN230020 · Decided Dec 22, 2023 · 267 days after receipt
Device type: Post-Ablation Tissue Response Prediction Software (QZL) · Radiology & Imaging
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.